Group members

The links below lead to University directory

Michael Welsh

The overall aims of our studies are to increase our understanding of leukemia progression and solid tumor metastasis by usage of the Shb-gene knockout model. These tumor processes will in particular be related to immune cell responses. The project involves both in vivo and in vitro experimentation and in an extension it is hoped that small molecular weight inhibitors of Shb function can be found that have an application in medicine.


The Shb gene in tumor biology.

Shb is an SH2-domain adapter protein operating downstream of tyrosine kinase receptors such as the VEGFR-2, FGFR-1, PDGF-receptors and the T cell receptor. The effects of Shb are pleiotropic and context dependent. We have recently generated a Shb-knockout mouse to assess the physiological relevance of Shb in vivo.

We observe impaired glucose homeostasis due to insufficient insulin secretion in the absence of Shb. In addition, the beta-cells exhibit reduced stress sensitivity. These effects on beta-cells are at least partly due to deregulated focal adhesion kinase signaling.
Shb-knockout mice display reproductive abnormalities with a transmission ratio distortion of the knockout allele related to female reproduction. Consequently, oocyte maturation is impaired in the absence of Shb and this relates to abnormal signaling via the ERK-RSK-S6 pathway. In addition to aberrant oocyte maturation, Shb-knockout embryos are morphologically abnormal and do not implant well. 
Shb-knockout mice also display reduced angiogenesis and this causes diminished tumor expansion (subcutaneously injected tumor cells or inheritable RIP-Tag insulinomas). Endothelial cells without Shb have an abnormal cytoskeleton and adherens junctions that may contribute to deficient angiogenesis. In addition, Shb-knockout vascular physiology shows signs of compensatory mechanisms (increased blood flow and an increased frequency of intermediately sized arterioles as determined by micro-CT) to counteract the adverse effects of the endothelial dysfunction. These aberrations are not due to regulatory roles of myeloid cells but reflect an inherent impairment of the vasculature. The Shb-knockout vasculature also confers increased metastasis of B16F10 melanomas due to increased vascular leakage and reduced recruitment of CD8+ cytotoxic T cells.
The absence of Shb exerts effects on hematopoiesis and peripheral T lymphocyte function. CD4+ T lymphocytes show a Th2 skewing of their response to stimulation in the absence of Shb and this confers increased allergic responses.
Hematopoietic stem cells show less proliferation in the absence of Shb due to elevated focal adhesion kinase activity. When examining BCR-ABL1-induced myeloid leukemia is the absence of Shb, a more severe disease disease developed. Again, this phenotype appeared to result from increased activity of focal adhesion kinase.

Current efforts aim at understanding the role of Shb in hematopoietic malignancies and how it affects immune surveillance against tumor cells.

Ongoing Projects...


For further information about this research group please contact
Professor Michael Welsh

Financial support

2017-2019

Swedish Research Council

Endothelial and immune cell interactions in tumor metastasis


2016-2018

Cancerfonden


Function of Shb in relation to leukemia and tumor metastasis.


2016

Family Ernfors Foundation

Role of SHB/FAK interactions in beta-cell function



Collaborators

outside the Department of Medical Cell Biology:

  • Lena Claesson-Welsh (Uppsala University),
  • Guillem Genové (Karolinska Institutet, Stockholm, Sweden),
  • Gustavo Mostoslavsky (Boston University, Boston, USA),
  • Jeff Tyner (Oregon Health & Science University, Portland, OR, USA)